How Are Rare Phototoxic Disorders Driving 9.1% CAGR Growth in the Afamelanotide Market? According to a new report from Intel Market Research, the global Afamelanotide market was valued at USD 136.27 million in 2026 and is projected to reach USD 258.01 million by 2034, growing at a robust CAGR of 9.1% during the forecast period (2026–2034). This growth is propelled by the increasing global prevalence of rare phototoxic disorders, heightened awareness about orphan diseases, and advancements in melanocortin-based peptide therapies. https://www.intelmarketresearch.com/download-free-sample/912/Server-Automation-Market